BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug

Reuters09-29
BUZZ-Larimar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> tumbles on safety concerns over rare genetic disorder drug

** Shares of Larimar Therapeutics LRMR.O fall 31% to $3.50 premarket on safety concerns about its experimental drug, nomlabofusp, after data from a long-term study

** Drug was being tested for Friedreich's ataxia, a rare genetic disorder that causes progressive damage to the nervous system

** Seven participants experienced anaphylaxis within the first 6 weeks of dosing and were withdrawn from the study, co says

** Anaphylaxis is a sudden and severe allergic reaction that can cause breathing problems, swelling and a drop in blood pressure

** "The major downside is that we continue to see anaphylaxis" - Jones Trading analyst Catherine Novack

** As of last close, stock up 31% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment